By using this site, you agree to the Privacy Policy and Terms of Use.
Accept

Science, Space & Technology

Space Science Digital
Contact
Search
  • Home
  • Environment

    the Great Bear’s grand-design spiral galaxy 

    March 13, 2023

    What’s Earth’s most distant spacecraft?

    April 4, 2023

    Balloon-borne telescope captures Tarantula Nebula in first research images

    April 21, 2023

    A luminous Seyfert galaxy and its active black hole-driven nucleus

    May 10, 2023
  • Space Flight

    Japan’s H3 rocket self-destructs following launch failure

    March 7, 2023

    Dark energy may have been hiding in the cores of black holes all along

    February 15, 2023

    Rocket Lab launches two commercial radar satellites

    March 16, 2023

    JWST captured the most thrilling and inspiring space images of 2022

    December 14, 2022
  • Cosmology

    The Sky This Week from February 17 to 24

    February 17, 2023

    Astronauts Could Clear Lunar Dust Away with Nitrogen Spray

    March 10, 2023

    The State of Suborbital Space Science

    March 15, 2023

    Another Look at the Aftermath of DART’s Impact Into Dimorphos

    March 22, 2023
  • Latest
  • About Us
Reading: Antibody fragment-nanoparticle therapeutic eradicates gastric cancer, shows research
Share
Aa
Space Science DigitalSpace Science Digital
  • Environment
  • Space Flight
  • Cosmology
  • Technology
Search
  • Home
  • Categories
    • Environment
    • Technology
    • Cosmology
    • Space Flight
  • More Foxiz
    • Blog Index
    • Forums
    • Complaint
    • Sitemap
Follow US
© 2023 Space Science Digital. All Rights Reserved.
Space Science Digital > Blog > Technology > Antibody fragment-nanoparticle therapeutic eradicates gastric cancer, shows research
Technology

Antibody fragment-nanoparticle therapeutic eradicates gastric cancer, shows research

By Aimee Daly March 16, 2023 6 Min Read
Share

[ad_1]

Antibody fragment-nanoparticle therapeutic eradicates cancer
Conceptual illustration of C’ dot nanoparticles adapted with HER2-targeting antibody fragments (dark blue and green) and cancer-killing drugs (teal), entering a tumor cell via HER2 receptors (orange). Credit: Ella Maru Studio/Provided

A novel cancer therapeutic, combining antibody fragments with molecularly engineered nanoparticles, permanently eradicated gastric cancer in treated mice, a multi-institutional team of researchers found.

The results of the “hit and run” drug delivery system, published in the March issue of Advanced Therapeutics, were the culmination of more than five years of collaboration between Cornell, the Memorial Sloan Kettering Cancer Center (MSKCC) and biopharmaceutical company AstraZeneca.

“I’ve seen beautiful results before, but I’ve never seen something that eradicates a tumor like this,” said study co-lead author Dr. Michelle Bradbury, MSKCC director of intraoperative imaging and professor of radiology at Weill Cornell Medicine.

The other co-lead authors are Ulrich Wiesner, the Spencer T. Olin Professor in the Department of Materials Science and Engineering, at Cornell Engineering; and J. Anand Subramony, vice president of protein engineering research and development at AstraZeneca at the time of the study.

Targeted cancer treatments such as antibody and nanoparticle therapies have seen narrow clinical use because of each therapy’s limitations, but the new therapeutic—an evolution of what the researchers call Cornell prime dots, or C’ dots—combines the best attributes of both into an ultrasmall, powerfully effective system.

As silica nanoparticles just 6 nanometers in size, C’ dots are small enough to penetrate tumors and safely pass through organs once injected into the body. Wiesner first developed them more than 15 years ago and, in collaboration with Bradbury, published a 2018 study that found an antibody fragment-nanoparticle hybrid to be especially effective in finding tumors.

This collaborative work with AstraZeneca set off the search for a new, molecularly engineered therapeutic version of this immuno-conjugate.

AstraZeneca “site engineered” fragments of antibodies so they would effectively attach to the C’ dots and target HER2 proteins associated with gastric cancer. The team optimized fragment conjugation to the C’ dot surface, along with specialized inhibitor drugs developed by AstraZeneca. This enabled the nanoparticles to carry about five times more drugs than most antibodies.

The final product was a version of C’ dots, armed with cancer-targeting antibody fragments and a large drug payload, all packed into a sub-7-nanometer, drug-immune conjugate therapy—a first of its kind in that size class, according to the researchers.

“We describe the mode of action as ‘hit and run,'” Wiesner said, “because the C’ dots either target the tumor microenvironment and kill the tumor cells or get safely cleared out of the body via renal clearance as a result of their small size, thereby minimizing off-target accumulation and associated side effects and toxicity.”

Mice with gastric cancer received three doses of the therapeutic. Not only did the treatment eradicate the disease in every mouse, but there was no evidence of tumor recurrence after nearly 200 days.

“Usually you’d have to couple the treatment with other therapies to see those kind of long-term results,” Bradbury said. “It showed that the very detailed, careful work of this team—the years spent on the stoichiometry and the surface chemical developments—it paid off.”

Bradbury underscored the versatility of the C’ dots platform, and said she envisions it being used not as a replacement for antibody treatments, but as a complementary tool that can be adapted to different types of cancers and other specific needs of patients.

“‘C’ dots have become unusually efficacious and safe in treating cancer. They completely obliterated the tumor, even at the cellular level,” said Wiesner. “This is what we ultimately had hoped for and it further supports our earlier decision to bet on therapeutic C’ dot applications.”

Wiesner and Bradbury said the research behind the new C’ dot therapeutic will be continued by Elucida Oncology, a startup company they founded to help bring the technology to market. They said that while Elucida is not using antibody fragments in their current clinical trial of C’ dots, the work will help them build new conjugates that can potentially utilize such fragments in future trials.

More information:
Li Zhang et al, Engineered Ultrasmall Nanoparticle Drug‐Immune Conjugates with “Hit and Run” Tumor Delivery to Eradicate Gastric Cancer, Advanced Therapeutics (2022). DOI: 10.1002/adtp.202200209

Provided by
Cornell University


Citation:
Antibody fragment-nanoparticle therapeutic eradicates gastric cancer, shows research (2023, March 16)
retrieved 16 March 2023
from https://phys.org/news/2023-03-antibody-fragment-nanoparticle-therapeutic-eradicates-gastric.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



[ad_2]

TAGGED: Antibody, cancer, eradicates, fragmentnanoparticle, gastric, Research, shows, therapeutic

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
[mc4wp_form]
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Aimee Daly March 16, 2023
Share this Article
Facebook Twitter Email Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SUBSCRIBE NOW

Subscribe to our newsletter to get our newest articles instantly!

[mc4wp_form]

HOT NEWS

Japan’s H3 rocket self-destructs following launch failure

Space Flight
March 7, 2023

Is that this black gap jet making stars explode?

Again to Article Listing Greater than twice the anticipated quantity of novae have been discovered…

October 27, 2024

NASA Says Spacecraft Crash Test Successfully Changes Asteroid’s Orbit

CAPE CANAVERAL, Fla. (AP) — A spacecraft that plowed into a small, harmless asteroid millions…

October 11, 2022

World-Saving Spacecraft Passes Test

NASA says its DART spacecraft successfully shifted the path of an asteroid. For us earthlings,…

October 11, 2022

YOU MAY ALSO LIKE

Staff develops transistors with sliding ferroelectricity based mostly on polarity-switchable molybdenum disulfide

Credit score: Yang et al. (Nature Electronics, 2023). Over the previous few years, engineers have been making an attempt to…

Technology
December 23, 2023

New Hubble Telescope picture exhibits mysterious spokes on Saturn’s rings

At first look, this picture of Saturn appears to be like as if it might be a shot from an…

News
December 22, 2023

Nuking an incoming asteroid will spew out X-rays, new mannequin exhibits

Final 12 months, a NASA mission proved that people might change an asteroid’s course by crashing into one with a…

News
December 22, 2023

Unimolecular self-assembled hemicyanine-oleic acid conjugate acts to eradicate most cancers stem cells: Research

Schematic illustration of unimolecular self-assembled CyOA NPs enhanced phototoxicity to CSCs by implementing oxygen-economical PDT. Credit score: Analysis Most cancers…

Technology
December 22, 2023
We use our own and third-party cookies to improve our services, personalise your advertising and remember your preferences.
  • Jobs Board
  • About Us
  • Contact Us
  • Privacy Policy
  • Exclusives
  • Learn How
  • Support
  • Solutions
  • Terms And Conditions
  • Editorial Policy
  • Marketing Solutions
  • Industry Intelligence

Follow US: 

Space Science Digital

Welcome to spacescience.digital, A source for the latest news and developments in the exciting field of space science. Our blog covers a wide range of topics, from the latest space missions and discoveries to updates on technology and scientific breakthroughs. We are passionate about sharing the wonders of the universe with our readers and providing them with engaging and informative content. Join us on this fascinating journey as we explore the mysteries of space and the frontiers of human knowledge.

© 2024 Space Science Digital. All Rights Reserved.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?